Introduction
• Increasing levels of antimicrobial resistance in clinical settings has increased pressure to find novel antibiotics, requiring searches in new environments.
• Fungus-farming ants have formed a symbiotic relationship with actinobacterial species to keep nests free of infectious disease, and to protect their farms from the invasive fungus Escovopsis [1, 2] .
• Additionally, up to 90% of biosynthetic gene clusters (BGCs) in actinobacteria are not expressed under standard laboratory conditions. These cryptic gene clusters must be 'mined' to maximise the likelihood of finding novel antimicrobial compounds.
• We have isolated 20 actinobacteria from the nests of fungus-farming ants and sequenced their genomes. Secondary metabolite analysis has been performed using antiSMASH and cryptic BGCs have been mined using a variety of nutrient media.
Methods
• DNA was extracted using the salting out method and highquality genome sequences have been produced.
• aptD and rpoB were used to analyse phylogeny.
• The filamentous strains included eight Streptomyces, two Amycolatopsis, one Nocardiopsis, one Jiangella, and five Pseudonocardia species
• The unicellular actinobacteria included two Tsukamurella and one Agrococcus species.
• antiSMASH 4.0 was used to identify the BCGs present, in total 394 were predicted to be present.
• These strains have been cultured on a variety of media, as shown in Table 1 .
• Overlays of Bacillus subtilis, Candida albicans and Escherichia coli were performed to determine bioactivity.
• Strains active against B subtilis or C albicans were further tested against MRSA or Scedosporium prolificans respectively.
Results
• UM15 and FG22, both Amycolatopsis species, have demonstrated activity
against all of the organisms tested but not on all of the media used.
• KY2, a Streptomyces species, has shown activity against all organisms except MRSA.
• antiSMASH analysis of FG22 identified a BGC for erythreapeptin with 100% similarity.
• UM15 contained a BGC with 75% similarity to a known erythreapeptin BGC and KY2 a 76% similarity for a candicidin BGC.
• These gene clusters fail to explain the range of activity seen by these strains, suggesting novel BGCs may be responsible for their bioactivity.
• KY4, another Streptomyces species, has no obvious BGCs encoding for an antibiotic but shows activity against B subtilis.
• Attempts to extract these antimicrobials have so far proven unsuccessful.
D Discussion
We have successfully isolated 20 actinobacteria from fungus-growing ants, and determined the bioactivity of these strains across a variety of media. Some strains have shown antimicrobial production on some media but no strain has shown activity on all of the media used.
Further work is required to determine the structure of the metabolites being produced, but this first requires a successful extraction. Where a strain contains a BGC with high similarity to a known antimicrobial, CRISPR will be used to remove the BGC. It is hoped that this will encourage the bacteria to activate a previously cryptic cluster encoding a novel antimicrobial. 
